BioBusiness

Univercells Expands Collaboration with University of Pennsylvania for Gene Therapy Manufacturing

July 24, 2024

Under the expanded agreement, Univercells and University of Pennsylvania will evaluate certain bioreactors for scalable gene therapy production.

EMA Accepts GSK Application for Blenrep Combinations in Multiple Myeloma Treatment

July 24, 2024

GSK’s submission is supported by Phase III trials showing significant progression-free survival benefit and positive overall survival trends using Blenrep combinations compared to standard care.

Agilent Expands Biopharma Offerings with BIOVECTRA Acquisition

July 22, 2024

The addition of BIOVECTRA’s biologics capabilities to accelerate drug development and manufacturing will allow Agilent to expand its end-to-end offerings for biopharma services.

AstraZeneca Strengthens Rare Disease Portfolio with Amolyt Pharma Acquisition

July 18, 2024

The acquisition adds a Phase III therapeutic peptide candidate to AstraZeneca’s late-stage pipeline for rare diseases.

Merck Completes EyeBio Acquisition, Strengthens Eye Disease Portfolio

July 17, 2024

The acquisition of EyeBio adds a late-phase antibody drug candidate for diabetic macular edema and neovascular age-related macular degeneration to Merck’s pipeline.

CordenPharma Expands its Peptide Platform in the US and Europe

July 17, 2024

The company plans to invest approximately €900 million (US$983 million) to expand its peptide platform at its Colorado, US, site and in Europe.

Johnson & Johnson Completes Numab Subsidiary Acquisition, Boosts Bispecific Antibody Pipeline

July 16, 2024

The acquisition adds NM26, a Phase II-ready bispecific antibody for treating atopic dermatitis, to Johnson & Johnson’s immune-mediated and inflammatory disease portfolio.

Thermo Fisher Scientific Completes Olink Acquisition, Boosts Proteomics Capabilities

July 12, 2024

With the acquisition, Olink will join Thermo Fisher’s Life Sciences Solutions business.

Pfizer Teams up with Evotec on Drug Discovery

July 11, 2024

Through a multi-year collaboration, Pfizer and Evotec aim to conduct early discovery research for therapeutics against metabolic and infectious diseases.

Sanofi's Dupixent Approved by EU as Targeted Therapy for Uncontrolled COPD

July 08, 2024

Other indications for which the Sanofi treatment has been approved include atopic dermatitis, asthma, and chronic rhinosinusitis.